Cancer Epigenomics
6th - 8th October 2013
- Organization:
- Cell Press
- Type:
- Symposium
- Venue:
- Hotel Melia
- Location:
- Sitges, Spain
- Website:
- Cancer Epigenomics
- Area
- Life Sciences
- Specialty
- Cancer
- Subject
- Cancer Research
Speakers
Stephen Baylin, Johns Hopkins, USA
Jay Bradner, Dana Farber Cancer Institute and Harvard Medical School, USA
Stephan Beck, University College London, UK
Emily Bernstein, Mount Sinai, USA
Lynda Chin, MD Anderson, USA
Dash Dhanak, GlaxoSmithKline, USA
Manel Esteller, IDIBELL, Spain
Thomas Graf, Center for Genomic Regulation, Spain
Piyush Gupta, Whitehead Institute and MIT, USA
Kristian Helin, University of Copenhagen, Denmark
Jan Korbel, EMBL, Germany
Tony Kouzarides, The Gurdon Institute, UK
Ben Lehner, Center for Genomic Regulation, Spain
Nicholas Navin, MD Anderson, USA
Bing Ren, University of California San Diego, USA
Victoria Richon, Epizyme, USA
Craig Thompson, Memorial Sloan-Kettering Cancer Center, USA
Christopher Vakoc, Cold Spring Harbor Laboratory, USA
Fiona Watt, King's College London, UK
Richard Young, Whitehead Institute and MIT, USA
Large-scale cancer genomics and genome-wide studies of the chromatin and DNA methylation landscape are reshaping our understanding of tumor heterogeneity, evolution, and genome stability. It is clear that epigenetic regulators are critical mediators of cancer progression and drug resistance, and new classes of targeted therapeutics against epigenetic regulators are already in clinical trials.
Our goal in organizing this meeting is to gather together experts on cancer, genomics, chromatin, systems biology, and chemical biology to discuss the rapidly advancing field of cancer epigenomics and its imminent impact on new cancer therapies. We aim to provide a forum for discussion and potential future collaboration amongst clinicians, drug development companies, and those at the forefront of basic biological discovery. The ultimate goal is to advance this exciting aspect of cancer biology and inform the epigenetic cancer therapies of tomorrow.
Subtopics
- Cancer genomics, epigenomics, and epigenetic drivers
- Epigenetic influences on genome stability
- Molecular underpinnings of therapeutic targets
- Aberrant DNA methylation in cancer
- Tumor heterogeneity
